Published in J Clin Invest on May 08, 2014
The transcription factor NFAT promotes exhaustion of activated CD8⁺ T cells. Immunity (2015) 1.94
Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun (2015) 1.13
T cell metabolic fitness in antitumor immunity. Trends Immunol (2015) 1.12
Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol (2015) 1.02
CDK4/6 inhibition triggers anti-tumour immunity. Nature (2017) 0.99
TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest (2015) 0.96
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol (2016) 0.94
Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy. J Natl Cancer Inst (2015) 0.92
Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity. Nature (2016) 0.91
Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming. Nat Commun (2015) 0.91
Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res (2016) 0.88
Visualizing T Cell Migration in situ. Front Immunol (2014) 0.85
T-cell exhaustion in allograft rejection and tolerance. Curr Opin Organ Transplant (2015) 0.82
New insights into the mechanisms of Treg function. Curr Opin Organ Transplant (2015) 0.80
CD28-CD80 interactions control regulatory T cell motility and immunological synapse formation. J Immunol (2014) 0.79
Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine. JCI Insight (2016) 0.78
Immunomodulatory antibody therapy of cancer: the closer, the better. Clin Cancer Res (2014) 0.75
Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy. Elife (2016) 0.75
In Vivo Imaging Sheds Light on Immune Cell Migration and Function in Cancer. Front Immunol (2017) 0.75
Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease. Front Immunol (2017) 0.75
Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways. Sci Rep (2016) 0.75
Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment. Nat Commun (2017) 0.75
IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment. Cancer Immunol Immunother (2017) 0.75
Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. Immunotherapy (2017) 0.75
Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer. Exp Ther Med (2017) 0.75
Transcriptional and epigenetic regulation of T cell hyporesponsiveness. J Leukoc Biol (2017) 0.75
Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer. Cell Rep (2017) 0.75
CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Cancer Immunol Immunother (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 12.67
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol (2001) 12.00
How regulatory T cells work. Nat Rev Immunol (2008) 11.66
T cell exhaustion. Nat Immunol (2011) 11.08
Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol (2012) 9.75
FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell (2006) 9.24
Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol (2000) 9.15
Origin of regulatory T cells with known specificity for antigen. Nat Immunol (2002) 7.49
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature (2007) 7.04
CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol (2007) 6.94
Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity (2004) 6.89
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Tumor antigens recognized by T lymphocytes. Annu Rev Immunol (1994) 6.16
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 5.20
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 4.96
Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J Exp Med (1994) 4.91
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69
Regulatory T cells in tumor immunity. Int J Cancer (2010) 4.53
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med (2003) 4.39
In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A (2003) 4.18
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature (2009) 4.03
Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity (2006) 3.92
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Adaptation of TCR repertoires to self-peptides in regulatory and nonregulatory CD4+ T cells. J Immunol (2007) 3.47
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A (2008) 3.40
Intravital microscopy: visualizing immunity in context. Immunity (2004) 3.37
Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity (2009) 3.32
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity (2010) 3.27
Aire-dependent thymic development of tumor-associated regulatory T cells. Science (2013) 3.23
CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J Immunol (1996) 3.02
Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med (2012) 2.97
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med (2007) 2.89
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol (2006) 2.71
Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity (2014) 2.58
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res (2007) 2.57
Generation of CD4(+)CD25(+) regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by endogenous TCR expression. J Immunol (2002) 2.56
Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest (2008) 2.52
Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med (2006) 2.43
Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem Cell Biol (2008) 2.39
Autoantigen-specific TGFbeta-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol (2007) 2.32
Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci U S A (2006) 2.17
CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res (2010) 1.91
The initial phase of an immune response functions to activate regulatory T cells. J Immunol (2009) 1.88
Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res (1980) 1.87
CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. J Exp Med (2013) 1.83
Preferential recognition of self antigens despite normal thymic deletion of CD4(+)CD25(+) regulatory T cells. J Immunol (2002) 1.55
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology (2012) 1.47
Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest (2010) 1.40
Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol (2008) 1.38
The basis for TCR-mediated regulation of the IL-2 receptor alpha chain gene: role of widely separated regulatory elements. EMBO J (2002) 1.36
Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology (2013) 1.35
Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. Immunity (2010) 1.32
The transcription factor NFAT exhibits signal memory during serial T cell interactions with antigen-presenting cells. Immunity (2013) 1.17
Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest (2009) 1.17
Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor. Eur J Immunol (2003) 1.14
T cell and APC dynamics in situ control the outcome of vaccination. J Immunol (2010) 1.11
Multiple treg suppressive modules and their adaptability. Front Immunol (2012) 1.01
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
Homing and cellular traffic in lymph nodes. Nat Rev Immunol (2003) 7.23
Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature (2007) 4.88
T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol (2008) 4.52
Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol (2008) 4.17
HIV-infected T cells are migratory vehicles for viral dissemination. Nature (2012) 3.57
Intravital microscopy: visualizing immunity in context. Immunity (2004) 3.37
Definition of germinal-center B cell migration in vivo reveals predominant intrazonal circulation patterns. Immunity (2007) 3.07
Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity (2009) 2.98
CCR7 ligands stimulate the intranodal motility of T lymphocytes in vivo. J Exp Med (2007) 2.81
The actin cytoskeleton in T cell activation. Annu Rev Immunol (2008) 2.62
HS1 functions as an essential actin-regulatory adaptor protein at the immune synapse. Immunity (2006) 2.23
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood (2009) 1.89
CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. Immunity (2012) 1.85
A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress. J Exp Med (2007) 1.71
Defective Th1 cytokine gene transcription in CD4+ and CD8+ T cells from Wiskott-Aldrich syndrome patients. J Immunol (2006) 1.44
Under "real world" conditions, desflurane increases drug cost without speeding discharge after short ambulatory anesthesia compared to isoflurane. Can J Anaesth (2004) 1.38
In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell (2012) 1.28
Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia (2009) 1.28
A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses. PLoS One (2007) 1.26
The transcription factor NFAT exhibits signal memory during serial T cell interactions with antigen-presenting cells. Immunity (2013) 1.17
Multi-photon microscopy with a low-cost and highly efficient Cr:LiCAF laser. Opt Express (2008) 1.15
Regulation of T-cell migration and effector functions: insights from in vivo imaging studies. Immunol Rev (2008) 1.14
Antigen availability determines CD8⁺ T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity (2013) 1.09
Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther (2004) 1.06
The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med (2009) 1.06
Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther (2006) 1.03
An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer (2011) 1.02
Specific and covalent labeling of a membrane protein with organic fluorochromes and quantum dots. Proc Natl Acad Sci U S A (2007) 0.99
A novel endothelial L-selectin ligand activity in lymph node medulla that is regulated by alpha(1,3)-fucosyltransferase-IV. J Exp Med (2003) 0.98
In vivo imaging of T cell priming. Sci Signal (2008) 0.95
Yttrium-90 microsphere induced gastrointestinal tract ulceration. World J Surg Oncol (2008) 0.94
The fate of autoreactive, GFP+ T cells in rat models of uveitis analyzed by intravital fluorescence microscopy and FACS. Int Immunol (2004) 0.93
Multiphoton intravital microscopy to study lymphocyte motility in lymph nodes. Methods Mol Biol (2012) 0.93
Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: analysis of function and distribution in lymphoid organs. J Allergy Clin Immunol (2010) 0.92
ACR Appropriateness Criteria ® spinal bone metastases. J Palliat Med (2012) 0.92
Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. Nat Med (2012) 0.91
Stereotactic body radiation therapy for hepatocellular carcinoma. Discov Med (2010) 0.89
Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int J Cancer (2003) 0.88
Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol (2013) 0.87
ACR Appropriateness Criteria® non-spine bone metastases. J Palliat Med (2012) 0.83
Intravital microscopy in BLT-humanized mice to study cellular dynamics in HIV infection. J Infect Dis (2013) 0.83
Uncoupling CD21 and CD19 of the B-cell coreceptor. Proc Natl Acad Sci U S A (2009) 0.82
Intravital imaging of CD8+ T cell function in cancer. Clin Exp Metastasis (2008) 0.82
FcRγ promotes T cell apoptosis in Fas-deficient mice. J Autoimmun (2013) 0.82
Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Brachytherapy (2007) 0.81
Addition of a carbohydrate-binding module enhances cellulase penetration into cellulose substrates. Biotechnol Biofuels (2013) 0.81
Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion. Brachytherapy (2007) 0.80
Large Syncytia in Lymph Nodes Induced by CCR5-Tropic HIV-1. AIDS Res Hum Retroviruses (2015) 0.78
The multidisciplinary management of giant cell tumor of bone. Expert Rev Anticancer Ther (2014) 0.78
CD44 keeps tumor killers polarized. Immunity (2008) 0.77
Use of nfsB, encoding nitroreductase, as a reporter gene to determine the mutational spectrum of spontaneous mutations in Neisseria gonorrhoeae. BMC Microbiol (2009) 0.76
Radiation therapy for intrahepatic malignancies. Expert Rev Anticancer Ther (2009) 0.76
Autocrine IFNγ controls the regulatory function of lymphoproliferative double negative T cells. PLoS One (2012) 0.76
FcRγ controls the fas-dependent regulatory function of lymphoproliferative double negative T cells. PLoS One (2013) 0.75
Corrigendum to "Evidence for Long-term Efficacy and Safety of Gene Therapy for Wiskott-Aldrich Syndrome in Preclinical Models". Mol Ther (2016) 0.75
Current understanding of the Wiskott-Aldrich syndrome and prospects for gene therapy. Expert Rev Clin Immunol (2007) 0.75